Literature DB >> 8782348

Protection of rabbits against rabbit viral haemorrhagic disease with a vaccinia-RHDV recombinant virus.

S Bertagnoli1, J Gelfi, F Petit, J F Vautherot, D Rasschaert, S Laurent, G Le Gall, E Boilletot, J Chantal, C Boucraut-Baralon.   

Abstract

In order to protect domestic and wild rabbits against RVHD, we constructed a recombinant vaccinia-RHDV virus, using the Copenhagen strain of the vaccinia virus. This recombinant virus expressed the RHDV capsid protein (VP60). Analysis of the expressed product showed that the recombinant protein, which is 60 kDa in size, was antigenic as revealed by its reactions in immunoprecipitation and indirect immunofluorescence with the antibodies raised against RHDV. The recombinant virus induced high level of RHDV specific antibodies in rabbits following immunization. Inoculations by both the intradermal and oral routes allow protection of animals against a challenge with virulent RHDV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782348     DOI: 10.1016/0264-410x(95)00232-p

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Strict Assembly Restriction of Peptides from Rabbit Hemorrhagic Disease Virus Presented by Rabbit Major Histocompatibility Complex Class I Molecule RLA-A1.

Authors:  Qingxu Zhang; Kefang Liu; Can Yue; Di Zhang; Dan Lu; Wenling Xiao; Peipei Liu; Yingze Zhao; Guolan Gao; Chunming Ding; Jianxin Lyu; William J Liu
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus.

Authors:  J Bárcena; M Morales; B Vázquez; J A Boga; F Parra; J Lucientes; A Pagès-Manté; J M Sánchez-Vizcaíno; R Blasco; J M Torres
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus.

Authors:  S Castañón; M S Marín; J M Martín-Alonso; J A Boga; R Casais; J M Humara; R J Ordás; F Parra
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Early acute depletion of lymphocytes in calicivirus-infected adult rabbits.

Authors:  Raquel M Marques; António Costa-E-Silva; Artur P Aguas; Luzia Teixeira; Paula G Ferreira
Journal:  Vet Res Commun       Date:  2010-08-11       Impact factor: 2.459

Review 5.  Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review.

Authors:  Joana Abrantes; Wessel van der Loo; Jacques Le Pendu; Pedro J Esteves
Journal:  Vet Res       Date:  2012-02-10       Impact factor: 3.683

Review 6.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

7.  Codon optimization of the rabbit hemorrhagic disease virus (RHDV) capsid gene leads to increased gene expression in Spodoptera frugiperda 9 (Sf9) cells.

Authors:  Jingpeng Gao; Chunchun Meng; Zongyan Chen; Chuanfeng Li; Guangqing Liu
Journal:  J Vet Sci       Date:  2013-06-30       Impact factor: 1.672

8.  Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease.

Authors:  J M Torres; M A Ramírez; M Morales; J Bárcena; B Vázquez; E Espuña; A Pagès-Manté; J M Sánchez-Vizcaíno
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

9.  Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine.

Authors:  Erlinda Fernández; Jorge R Toledo; Lídice Méndez; Nemecio González; Francisco Parra; José M Martín-Alonso; Miladys Limonta; Kosara Sánchez; Ania Cabrales; Mario P Estrada; Alina Rodríguez-Mallón; Omar Farnós
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

Review 10.  Review of companion animal viral diseases and immunoprophylaxis.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2008-11-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.